Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter ended September 30, 2009, and on recent developments and future outlook. Cardium made significant progress since its second quarter 2009 financial report and highlights included:

  • Sale of Cardium's InnerCool Therapies business to Royal Philips Electronics;
  • Completion and announcement of data from the Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of non-healing diabetic ulcers and the Company's plans to meet with the FDA to review the data and proposed outline for a Phase 3 clinical study;
  • Plans for the commercial development of a new product candidate Excellagen(TM), a collagen-based topical gel, through a FDA 510(k) clearance pathway for potential use by physicians in patients with topical wounds, which include diabetic ulcers as well as pressure ulcers, venous ulcers, surgical and trauma wounds, second degree burns, and other types of wounds;
  • Publication of positive findings from the open label multi-center Phase 1/2 Excellarate clinical study in the October 2009 issue of Wound Repair and Regeneration, a peer-reviewed journal of the Wound Healing Society;
  • Plans to develop a DNA-based orthobiologics product portfolio based on a reformulation of the Company's Excellarate product candidate that will initially focus on non-union bone fractures and spinal fusions;
  • Publication of preclinical research published in the scientific journal, Gene Therapy, demonstrating the potential benefits of the Cardium's Gene Activated Matrix technology for accelerating and enhancing periodontal tissue repair and oral implant osseointegration;
  • Completion of two registered direct investments of Cardium's common stock by institutional invest
    '/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... has announced an exclusive contract with Trek Bicycle Corporation ... and Leum Software intend to enhance the current Ascend software ... help them manage their business with increased efficiency. , ,We ... successful. In the future, a dealers success will depend more ...
... effort to gather a burgeoning number of stem cell ... the University of Wisconsin-Madison has established the new Wisconsin ... of the UW-Madison Graduate School, the new initiative is ... efforts to develop new resources and opportunities for as ...
... Companies that do not specialize in software, but incorporate ... products, more often than not, overlook the importance of ... biggest feature or the most prevalent feature of the ... can and should be protected. , ,For example, ...
Cached Biology Technology:UW Madison launches new stem cell research program 2Beyond the screws and gears: Protecting your products by protecting your software 2
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... one of the first efforts of its kind, UCLA researchers have ... showing not just the order in which genes fall in the ... findings, published in the August issue of the journal Genome ... and shed light on how they collaborate to help cells thrive ...
... mortality worldwide, accounting for more than one in ten deaths. ... million. The ESMO Congress provides a major international forum for ... Congress Program Highlights , , New ... new drugs to treat ovarian, skin, colorectal and other cancers, ...
... world is diagnosed with breast cancer every 23 seconds. It ... and approximately 456,000 die from the disease each year. At ... a scientist is taking aim at the molecular machinery behind ... G. Komen for the Cure, Catherine Denicourt, Ph.D., an assistant ...
Cached Biology News:UCLA scientists map all mammalian gene interactions 2UCLA scientists map all mammalian gene interactions 335th ESMO Congress media alert 235th ESMO Congress media alert 3
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Agarose Gel Loading Dye Mixture 6X...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Biology Products: